Vascular Biogenics Stock Forecast, Price & News

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

Is Vascular Biogenics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vascular Biogenics stock.
View analyst ratings for Vascular Biogenics or view top-rated stocks.

How has Vascular Biogenics' stock price been impacted by COVID-19?

Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VBLT shares have increased by 18.9% and is now trading at $1.45.
View which stocks have been most impacted by COVID-19.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 1,630,000 shares, a decrease of 20.9% from the December 15th total of 2,060,000 shares. Based on an average daily trading volume, of 201,800 shares, the short-interest ratio is presently 8.1 days.
View Vascular Biogenics' Short Interest.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Vascular Biogenics.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) issued its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative net margin of 3,612.61% and a negative trailing twelve-month return on equity of 66.02%. During the same period in the prior year, the business earned ($0.12) EPS.
View Vascular Biogenics' earnings history.

What price target have analysts set for VBLT?

4 brokers have issued 1 year price targets for Vascular Biogenics' stock. Their forecasts range from $4.00 to $7.00. On average, they expect Vascular Biogenics' stock price to reach $5.75 in the next year. This suggests a possible upside of 296.6% from the stock's current price.
View analysts' price targets for Vascular Biogenics or view top-rated stocks among Wall Street analysts.

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:

• Dror Harats, Chief Executive Officer & Director
• Eyal Breitbart, Vice President-Research & Operations
• Erez Feige, Vice President-Business Operations
• Samuel I. Backenroth, Chief Financial Officer
• Tami Rachmilewitz, Vice President-Clinical Development

Who are some of Vascular Biogenics' key competitors?

Some companies that are related to Vascular Biogenics include Avadel Pharmaceuticals (AVDL), Geron (GERN), Omeros (OMER), Khosla Ventures Acquisition (KVSA), Immuneering (IMRX), AC Immune (ACIU), Vaccitech (VACC), Pyxis Oncology (PYXS), BioDelivery Sciences International (BDSI), Zomedica (ZOM), XBiotech (XBIT), Adagene (ADAG), Evolus (EOLS), VistaGen Therapeutics (VTGN) and Viking Therapeutics (VKTX).
View all of VBLT's competitors.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Spectrum Planning & Advisory Services Inc. (0.03%).

Which major investors are buying Vascular Biogenics stock?

VBLT stock was purchased by a variety of institutional investors in the last quarter, including Spectrum Planning & Advisory Services Inc..

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.45.

How much money does Vascular Biogenics make?

Vascular Biogenics has a market capitalization of $90.43 million and generates $920 thousand in revenue each year. The biopharmaceutical company earns $-24.23 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Vascular Biogenics have?

Vascular Biogenics employs 38 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

Where are Vascular Biogenics' headquarters?

Vascular Biogenics is headquartered at 8 HASATAT STREET, MODI IN L3, 7178106.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at [email protected], or via fax at 972-8993-5001.